XenoPort Sinks On Psoriasis Drug Safety; No Big Gain For Fumarates?
This article was originally published in Scrip
Executive Summary
XenoPort Inc. touted the positive efficacy of XP23829 in a Phase II psoriasis clinical trial on Sept. 15, but the Santa Clara, California-based company's stock sank 28.1% to close at $4.84 per share based on safety concerns for its prodrug of monomethyl fumarate (MMF).